Valeo Financial Advisors LLC Sells 299 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Valeo Financial Advisors LLC decreased its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 5.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,713 shares of the medical research company’s stock after selling 299 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Laboratory Co. of America were worth $1,310,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mcrae Capital Management Inc. raised its holdings in shares of Laboratory Co. of America by 1.6% in the fourth quarter. Mcrae Capital Management Inc. now owns 84,446 shares of the medical research company’s stock valued at $19,365,000 after buying an additional 1,295 shares during the last quarter. Asset Management One Co. Ltd. increased its position in Laboratory Co. of America by 3.8% in the 4th quarter. Asset Management One Co. Ltd. now owns 32,799 shares of the medical research company’s stock valued at $7,558,000 after acquiring an additional 1,205 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Laboratory Co. of America by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,916,505 shares of the medical research company’s stock worth $437,357,000 after acquiring an additional 51,045 shares during the last quarter. Mill Creek Capital Advisors LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter worth approximately $347,000. Finally, Kestra Private Wealth Services LLC grew its stake in shares of Laboratory Co. of America by 132.6% during the fourth quarter. Kestra Private Wealth Services LLC now owns 3,056 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 1,742 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on LH shares. Barclays reduced their price objective on Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. HSBC raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research note on Wednesday, October 30th. UBS Group lowered their price objective on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. StockNews.com upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Bank of America lifted their price target on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $265.31.

Laboratory Co. of America Stock Up 0.8 %

NYSE:LH opened at $246.74 on Friday. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59. The stock has a 50-day moving average price of $237.42 and a two-hundred day moving average price of $230.91. The stock has a market cap of $20.64 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.84 and a beta of 1.07. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, equities analysts expect that Laboratory Co. of America Holdings will post 15.96 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio is currently 32.65%.

Insider Buying and Selling

In other news, EVP Glenn A. Eisenberg sold 11,711 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $240.43, for a total value of $2,815,675.73. Following the sale, the executive vice president now owns 31,289 shares of the company’s stock, valued at $7,522,814.27. The trade was a 27.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. This trade represents a 7.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,504 shares of company stock valued at $5,905,692. Company insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.